Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 9/20 | 0.36 |
| ▸ | MAOB | P27338 | 9/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323971 | 0.81 | CSF1R (0.36) | KDM4E | |
| SCHEMBL22325386 | 0.77 | ALOX5 (0.33) | EGFR | |
| SCHEMBL29380606 | 0.77 | CSF1R (0.36) | KDM4EEGFR | |
| SCHEMBL22323706 | 0.77 | CSF1R (0.36) | KDM4EEGFR | |
| SCHEMBL29447055 | 0.76 | KDM4E (0.46) | KDM4EMAOAMAOBSIGMAR1FTO | |
| SCHEMBL22324505 | 0.76 | KDM4E (0.46) | KDM4EMAOAMAOBSIGMAR1FTO | |
| SCHEMBL22325384 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL21410221 | 0.72 | EGFR (0.39) | EGFR | |
| SCHEMBL30973537 | 0.72 | EGFR (0.39) | EGFR | |
| SCHEMBL22324259 | 0.72 | PDE10A (0.32) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509460-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| CN-114126613-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3920926-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020163541-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020922-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | KDM4E 2530/4885MAOA 4459/4885MAOB 3954/4885 |
| US-12509460-B2 | Methods and compositions for modulating splicing | SF3B1, RTCB, RBM17 | KDM4E 2036/4885MAOA 4073/4885MAOB 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.